Essais liés9clinical trials
VilleMineolalocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT06096779

Ouvrir le site du centre

Essais cliniques associés

9
MoléculeIndication / populationPhaseNCTTitreStatut
Atezolizumab Cancer Phase 2 NCT06096779 Kirros — A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis ACTIVE_NOT_RECRUITING
Biospecimen Collection Cancer Phase 3 NCT06058377 Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer RECRUITING
Biopsy Procedure Cancer Phase 1/2 NCT05896839 Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer RECRUITING
Biospecimen Collection Cancer Phase 3 NCT05675410 A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab RECRUITING
Biospecimen Collection Cancer Phase 3 NCT05256225 Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma RECRUITING
Bone Scan Cancer Phase 2/3 NCT05691478 A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma SUSPENDED
Biospecimen Collection Lupus Phase 1 NCT03816345 Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO RECRUITING
Biospecimen Collection Cancer Phase 2/3 NCT06203600 Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial RECRUITING
Anastrozole Cancer Phase 3 NCT07391774 Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial RECRUITING